SL
SLNCF.US Silence Therapeutics plc
- Market cap
- USD 1.22B
- P/E
- -
- P/B
- 5.66x
- ROE
- -24.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SLNCF.US undervalued?
Graham numberThe Graham number of Silence Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Silence Therapeutics plc fundamental analysis
No fundamental analysis for Silence Therapeutics plc yet.
Silence Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease…
Full company profileSilence Therapeutics plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Silence Therapeutics plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 770K | 16.0K | 0.00 | 244K | 5.48M | 12.4M | 17.7M | 25.4M | 43.3M | 559K | 562K |
| Gross Profit | -7.94M | -7.93M | -9.74M | 244K | 1.72M | 4.96M | 6.68M | 15.1M | 31.4M | 344K | 120K |
| Operating Income | -11.9M | -14.4M | -20.6M | -22.7M | -35.8M | -45.8M | -49.8M | -49.6M | -63.3M | -89.8M | -56.5M |
| EBITDA | -11.6M | -3.33M | -20.2M | -22.4M | -35.5M | -45.4M | -39.9M | -49.8M | -49.1M | -88.0M | -53.5M |
| Net Income | -8.44M | -1.62M | -18.4M | -19.6M | -32.5M | -39.4M | -41.0M | -43.3M | -45.3M | -88.6M | -52.9M |
| EPS | -0.12 | -0.02 | -0.26 | -0.26 | -0.40 | -0.44 | -1.27 | -1.17 | -0.98 | -1.88 | -0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 55.8M | 55.0M | 38.9M | 46.1M | 86.0M | 96.2M | 108M | 94.5M | 162M | 131M | 281M |
| Total Liabilities | 1.61M | 2.66M | 3.83M | 25.2M | 76.9M | 87.7M | 85.4M | 77.1M | 54.8M | 69.1M | 66.5M |
| Shareholders' Equity | 54.2M | 52.4M | 35.1M | 20.9M | 9.06M | 8.53M | 22.1M | 22.0M | 107M | 62.3M | 215M |
| Cash & Short-term Investments | 39.0M | 43.1M | 26.5M | 33.5M | 37.4M | 73.5M | 71.1M | 54.4M | 118M | 85.1M | 248M |
| Total Debt | - | - | - | 287K | 341K | 137K | 446K | 274K | 93.5K | 160K | -87.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.1M | -9.60M | -16.8M | 1.73M | -10.8M | 9.19M | -57.0M | -39.4M | -54.1M | -62.3M | -35.8M |
| Capital Expenditure | 537K | 173K | 188K | 9.00K | 514K | 1.80M | 545K | 45.0K | 169K | 55.0K | 8.00 |
| Free Cash Flow | -10.6M | -9.77M | -16.9M | 1.72M | -11.3M | 7.39M | -57.6M | -39.4M | -54.2M | -62.3M | -35.8M |
| Ratios | |||||||||||
| ROE | -15.6% | -3.1% | -52.5% | -93.7% | -359.3% | -462.2% | -185.9% | -196.7% | -42.3% | -142.2% | -24.6% |
| ROA | -15.1% | -2.9% | -47.3% | -42.5% | -37.9% | -41.0% | -38.2% | -45.8% | -28.0% | -67.4% | -18.8% |
| Net Profit Margin | -1,096.1% | -10,112.5% | - | -8,025.4% | -594.0% | -317.4% | -232.4% | -170.5% | -104.7% | -15,851.9% | -9,411.1% |
| Debt to Equity | - | - | - | 0.01x | 0.04x | 0.02x | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Silence Therapeutics plc dividends
Silence Therapeutics plc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Apr 29, 2013.
Who owns Silence Therapeutics plc
- Insiders 6.65%
- Institutions 7.06%
- Public & others 86.29%
- Shares outstanding 187M
- Free float 160M
Silence Therapeutics plc company profile
- Company name
- Silence Therapeutics plc
- Ticker
- SLNCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Fiscal year end
- December
- Address
- 12 Hammersmith Grove, London, United Kingdom, W6 7AP
- Phone
- 44 20 3457 6900
- Website
- silence-therapeutics.com
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Silence Therapeutics plc management
9- Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.DInterim CEO & Chairman of the Board · born 1954
- Ms. Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director · born 1971
- Dr. Steven J. Romano M.D.Executive VP and Chief Research & Development Officer · born 1959
- Dr. Marie Wikstrom Lindholm Ph.D.Chief Scientific Officer
- Ms. Gem Gokmen HopkinsVP and Head of IR & Corporate Communications
- Mr. Jaimin B. ShahSVP & General Counsel
- Mr. J.P. GabrielChief Technical Operations Officer
- Mr. Curtis Rambaran M.D.Chief Medical Officer
- Ms. Marianna AnestiVP & Head of Business Development